Применение тоцилизумаба при ревматоидном артрите: новые данные

1. <div><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита – взгляд в 21 век. Клин мед 2005;6:8–12.</p><p>Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861–71.</p><p>Furst D.E., Keystone E.C., FleischmannR. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2010;69(Suppl. II): i2–i29.</p><p>Smolen J.S., Aletaha D., Bijsma J.W.J. et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.</p><p>Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.</p><p>Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010.</p><p>Malemud C.J. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatol: Res and Rev 2009;1:133–55.</p><p>Tanaka T., Narazaki M., KishimotoT. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199–219.</p><p>Насонов Е.Л. Новые возможности фармакотерапии ревматических болезней – ингибирование интерлейкина 6. Клин фармакол тер 2008;1:60–7.</p><p>Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64–71.</p><p>Насонов Е.Л. Применение тоцилизумаба (Актемры) при ревматоидном артрите. Науч-практич ревматол 2009;3(прил.):18–35.</p><p>Smolen J., Beaulieu A., Ruddert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008;371:987–97.</p><p>Genovese M.C., McKay J.D., NasonovE.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968–80.</p><p>Nishimoto N., Hashimoto J., Miaysaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162–7.</p><p>Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12–9.</p><p>Kremer J.L., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year; the LITHE study. Arthr Rheum 2011;63: 609–21.</p><p>Emery P., Keystone E., Tony H.-P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patientswith rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.</p><p>Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88–96.</p><p>Yazici Y., Curtis J.R., Ince A. et al. Efficacy of tocilizumab in patients with moderate to severe rheumatoid arthritis and previously inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2011;September 26 [Epub. ahead of print].</p><p>Dougados M., Kissel K., Amital H. et al. Double-blind study of tocilizumab plus methotrexate vs tocilizumab plus placebo in patients with active rheumatoid arthritis despite prior methotrexate: progression of structural damage, quality of life, and physical function at 24 weeks. Arthr Rheum 2011;63(Suppl.):S1032 (2628 abst.).</p><p>Bykerk V., Ostor A., Alvaro-Gracia J.M. et al. Tocilizumab in patients with rheumatoid arthritis and an inadequate response to DMARDs and/or the TNF inhibitor therapy: ACT-SURE preliminary results. Ann Rheum Dis 2010;69(Suppl. 3):379.</p><p>Bykerk V., Ostor A., Ivora J.A.R. et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and an inadequate response to previous treatments. Arthr Rheum 2011;63(Suppl.):S866 (2218 abst.).</p><p>Weinblatt E., Kremer J.M., Cush J.J. et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US Rheumatoid Arthritis population with inadequate response to amti-tumor necrosis factor agents. Arthr Rheum 2011;63(Suppl.):S162 (427 abst.).</p><p>Burmester G.R., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with avtive rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755–9.</p><p>Smolen J., Martinez-Avila J., AletahaD. Tocilizumab (TCZ) inhibits progression of joint damage in rheumatoid arthritis (RA) irrespective of its anti-inflammatory effects: dissociation of the linl between inflammation and destruction. Arthr Rheum 2011;63(Suppl.):S630 (1641 abst.).</p><p>Conaghan P.G., Peterfy C.G., DiCarloJ. et al. Early reduction in tissue inflammation with tocilizumab as either monotherapy or in combonation with methotrexate 12week unblended results from magnetic resonance imaging substudy of a randomized controlled trial. Arthr Rheum 2011;63(Suppl.):S165 (434 abst.).</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793–806.</p><p>Genovese M.C., Becker J.C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114–23.</p><p>Smolen J.S., Kay J., Doyle M.K. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–21.</p><p>Насонов Е.Л. Метотрексат. Перспективы применения в медицине. М.: Филоматис, 2005;196 с.</p><p>Bathon J.M., Martin R.W., FleischmannR.M. et al. Comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.</p><p>Genovese M.C., Bathon J.M., MartinR.W. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcome. Arthr Rheum 2002;46:1443–50.</p><p>Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al. The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate trearment. Arthr Rheum 2006;54:26–37.</p><p>Nishimto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010 [Epub. ahead of print].</p><p>Mao Mao An, Zui Zou, Hei Shen et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a metaanalysis of randomized controlled trials. Eur J Clin Pharmacol 2010 [Epub ahead of print].</p><p>Singh J.A., Beg S., Lopez-Olivo M.A. Tocilizumab for rheumatoid arthritis: a Cochrane systemic review. J Rheumatol 2010 [Epub. ahead of print].</p><p>Choy E., Isenberg D.A., Garrood T. et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin 6 receptor monoclonal antibody. Arthr Rheum 2002;46:3143–50.</p><p>Nishimoto N., Yoshizaka K., MiaysakaN. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr Rheum 2004;50:1761–9.</p><p>Maini R., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin 6 receptor antagonist, tocilizumab in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817–29.</p><p>Nishimoto N., Miyasaka N., YamamotoK. et al. Long-term safety and efficacy of tocilizumab, an antiinterleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study); evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008;68:1580–4.</p><p>Smolen J.S., Alten R.H.E., Gomez-Reino J. et al. Efficacy of tocilizumab (TCZ) in rheumatoid arthritis (RA): interim analysis of long-term extension trials of up to 2.5 years. Ann Rheum Dis 2009;68(Suppl. 3):401 (FRI0133).</p><p>Yamanaka H., Tanaka Y., Inoue E. et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2010[Epub. ahead of print].</p><p>Takeuchi T., Tanaka Y., Amano K. et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients – REACTION 52-week study. Rheumatology 2011; July 13 [Epub. ahead of print].</p><p>Tanaka Y., Takeuchi T., Amano K. et al. Impact of tocilizumab therapy after switching from tumor necrosis factor (TNF) inhibitors – prevention of joint damage by tocilizumab in patients with inadequate response to anti-TNF therapies. Arthritis Rheum 2011;63(Suppl.):S484 (1239 abst.).</p><p>Smolen J.S., Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthr Res Ther 2009;11:204.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов: Клинические рекомендации. М.: ИМАПРЕСС, 2009.</p><p>Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р. и др. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Науч-практич ревматол 2010;2:30–6.</p><p>Smolen J.S., Churchill M., Rizzo W. et al. Tocilizumab treatment results in rapid improvements in the signs and symptoms to moderate-to-severe rheumatoid arthritis in four patients populations with different prior therapy exposure. Arthr Rheum 2008;58(Suppl.):S532 (989).</p><p>Beaulieu A.D., McKay J.D., Pavelka K. et al. Treatment with the humanized antiinterleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from OPTION and TOWARD. Ann Rheum Dis 2008;67(Suppl. II):195.</p><p>Hirabayashi Y., Ishii T., HarigaeH. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheum Int 2010 (on line).</p><p>Nakashima Y., Kondo M., Harada H. et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20:343–52.</p><p>Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2011;4:11–6.</p><p>Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практич ревматол 2010;2:21–9.</p><p>Felson D.T., Smolen J.S., Wells G. et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthr Rheum 2011;63:573–86.</p><p>Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011; August 29 [Epub. ahead of print].</p><p>Kojima T., Kaneko A., Hirano V. et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol 2011; 20 September [Epub. ahead of print].</p><p>Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature rewires informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976–86.</p><p>Salliot C., Finckh A., Katchamart W. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis 2011;70:266–71.</p><p>Kristensen L.E., Jakobsen A.K., BartelsR.M. et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol 2010 [Epub. ahead of print].</p><p>Bergman G.J., Hochberg M.C., BoersM. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthr Rheum 2010;39:425–41.</p><p>Devine E.B., Alfonso-Cristancho R., Sullivan S.D. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy 2011;31:39–51.</p><p>Gallego-Galisteo M., Villa-Rabio A., Alerre-del Ray E. et al. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther 2011; March 25 [Epub. ahead of print].</p><p>Turksta E., Ng S.-K., Scuffham P.A. A mixed treatment comparison of the shot-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin 2011;27:1885–97.</p><p>Kaufmann J., Feist E., Schmidt H. et al. Comparison of the efficacy of tocilizumab and TNF- inhibitors on the DAS28 in «real life» conditions in rheumatoid arthritis (RA) patients after DMARD failure. Arthr Rheum 2010;62(Suppl.):S22.</p><p>Leffers H.C., Ostergaard M., GlintborgB. et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216–22.</p><p>Yoshida K., Tokuda Y., Oshikawa H. et al. An observational study of tocilizumab and TNF- inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology 2011; 2 September [Epub. ahead of print].</p><p>Yoshida K., Matsui K., Nakano H. et al. Tocilizumab and Tumor Necrosis Factor inhibitors in biologic switchers: similar drug survival and safety with different infection profile in routine practice. Arthr Rheum 2002;63(Suppl.):S852 (2187 abst.).</p><p>Smolen J.S., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthr Rheum 2011;63:43–52.</p><p>Curtis J.R., Ogale S., Devenport J., Lepley D. Effects of tocilizumab dose escalation on disease activity in adalts rheumatoid arthritis patients with inadequate response at 16 weeks. Arthr Rheum2011;63(Suppl.):S867 (2219 abst.).</p><p>Nishimoto N. Japanese MRA Study group for RA. Drug free remission after cessation of ACTEMRA monotherapy (DREAM study). Ann Rheum Dis 2010;69(Suppl. 3):98 (abst.).</p><p>Search J., Rath T., Laudes M. et al. A decrease in neutrophil counts following a single infusion of tocilizumab is predictive of low disease activity and remission after 24 weeks. Ann Rheum Dis 2010;69(Suppl. 3):499 (abst.).</p><p>Kawashiri S.-Y., Kawakami A., Iwamoto N. et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with high titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 2011; 15 January [Epub. ahead of print].</p><p>Sagawa A. The efficacy and safety of reinstitution of tocilizumab in patients with relapse active rheumatoid arthritis after long-term withdrawal of tocilizumab Modern Rheumatol 2010 [Epub. ahead of print].</p><p>Nishimoto N. Japanese MRA Study group for RA. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE Study). Ann Rheum Dis 2010;69(Suppl. 3):537 (abst.).</p><p>Schiff M.H., Kremer J.M., Jahreis A. et al. Integrated safety in tocilizumab clinical trials. Arthr Res Ther 2011;13:R141.</p><p>Genovese M.C., Sebba A., Rubbert-Roth A. et al. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials. Arthr Rheum 2011;63(Suppl.):S866 (2217 abst.).</p><p>Campbell L., Chen C., Bhagat S.S. et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systemic literature review and meta-analysis of randomized controlled trials. Rheumatology 2010; November 14 [Epub. ahead of print].</p><p>Yamanaka H., Harigai M., Inokuma S. et al. Postmarketting surveillance of tocilizumab for rheumatoid arthritis in Japan – full analysis report of 7901 patients. Arthr Rheum 2011;63(Suppl.):S1033 (2629 abst.).</p><p>Lang V., Englbrecht M., Rech J. et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology 2011 [Epub. ahead of print].</p><p>Bannwarth B., Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Exp Opin Drug Saf 2011;10:123–31.</p></div><br />